Trial Profile
A Phase 1 Single Escalating Dose Study to Assess the Safety and Pharmacokinetics of CTS21166 Administered Intravenously to Healthy Adult Males
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2008
Price :
$35
*
At a glance
- Drugs CTS 21166 (Primary) ; CTS 21166
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors CoMentis
- 26 Jul 2008 Results were presented at ICAD 2008.
- 05 Mar 2008 New trial record.